• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Shattuck Labs Inc.

    6/2/26 5:00:32 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STTK alert in real time by email
    8-K
    false 0001680367 0001680367 2026-05-28 2026-05-28
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 28, 2026

     

     

    Shattuck Labs, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39593   81-2575858

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

    500 W. 5th Street, Suite 1200

    Austin, TX 78701

    (Address of principal executive offices, including zip code)

    (512) 900-4690

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, par value $0.0001 per share   STTK   The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging Growth Company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    On Thursday, May 28, 2026, Shattuck Labs, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on April 2, 2026, the record date for the Annual Meeting, there were 75,581,787 shares of common stock entitled to vote at the meeting.

     

    Item 5.02.

    Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    At the Annual Meeting, the Company’s stockholders approved an amendment and restatement of the Company’s 2020 Equity Incentive Plan (as so amended, the “Plan”) to revise the calculation of the automatic annual increase in the number of shares of common stock available for issuance, increase the number of shares available for issuance under the Plan by 1,691,082 shares, and extend the Plan’s term to March 23, 2036.

    For additional information regarding the Plan, please refer to the heading “Summary of the Amended and Restated 2020 Equity Incentive Plan” contained in Proposal 5 of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2026 (the “Proxy Statement”), which description is incorporated herein by reference.

    The foregoing description of the Plan and the summary contained in the Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the Plan, a copy of which is filed as Exhibit 10.1 with this Current Report on Form 8-K and is incorporated herein by reference.

     

    Item 5.07.

    Submission of Matters to a Vote of Security Holders.

    At the Annual Meeting, each of the Company’s director nominees was elected, a frequency of one year received the plurality of votes cast on Proposal 4 and the other proposals voted on were approved. The final voting results are set forth below:

     

         Votes
    For
         Votes
    Withheld
         Broker
    Non-Votes

    Proposal 1. Election of Class III Director Nominees

            

    •

    Taylor Schreiber, M.D., Ph.D.

         51,347,234        2,860,512      10,607,421

    •

    Helen M. Boudreau

         50,110,095        4,097,651      10,607,421

    •

    Clay Siegall, Ph.D.

         50,388,129        3,819,617      10,607,421
         Votes
    For
       Votes
    Against
         Abstentions      Broker
    Non-Votes

    Proposal 2. Ratification of KPMG LLP as Independent Auditor

       64,802,807      7,317        5,043      0
         Votes
    For
       Votes
    Against
         Abstentions      Broker
    Non-Votes

    Proposal 3. Advisory Vote on Executive Compensation

       49,849,887      4,356,199        1,660      10,607,421
         1 Year    2 Years      3 Years      Abstentions    Broker
    Non-Votes

    Proposal 4. Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation

       53,948,458      21,627        237,643      18    10,607,421
         Votes
    For
       Votes
    Against
         Abstentions      Broker
    Non-Votes

    Proposal 5. Approval of Amendment and Restatement of the 2020 Equity Incentive Plan

       43,498,166      10,709,563        17      10,607,421

     

    2


    In light of these voting results, the Company plans to hold future advisory votes on executive compensation annually until the next required vote on the frequency of such advisory votes, or until the Board of Directors of the Company otherwise determines that a different frequency is in the best interests of the Company and its stockholders.

     

    Item 9.01.

    Financial Statements and Exhibits.

    Exhibits

     

    Exhibit
    Number
       Description of Exhibit
    10.1    Amended and Restated 2020 Equity Incentive Plan.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    3


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Shattuck Labs, Inc.
    Date: June 2, 2026     By:  

    /s/ Dr. Taylor Schreiber

          Dr. Taylor Schreiber
         

    Chief Executive Officer

    (principal executive officer)

     

    4

    Get the next $STTK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STTK

    DatePrice TargetRatingAnalyst
    4/27/2026Overweight
    Cantor Fitzgerald
    3/6/2026$25.00Buy
    Needham
    1/28/2026$15.00Overweight
    Piper Sandler
    12/1/2025$6.00Neutral → Buy
    H.C. Wainwright
    9/8/2025$4.00Outperform
    Wedbush
    3/17/2025$4.00Outperform
    Leerink Partners
    10/2/2024$8.00 → $2.00Buy → Neutral
    Citigroup
    10/2/2024Buy → Hold
    Needham
    More analyst ratings

    $STTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Golumbeski George

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    6/2/26 8:00:09 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ashiya Mona

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    6/2/26 8:00:06 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Baker Daniel G.

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    6/2/26 8:00:11 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights

    Phase 1 clinical trial of SL-325 enrollment complete; data expected in the second quarter of 2026 –Phase 2 clinical trial of SL-325 in patients with Crohn's disease expected to initiate in the third quarter of 2026 – AUSTIN, Texas and DURHAM, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2026 and provided recent business highlights. "We are pl

    5/7/26 6:15:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights

    Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 –Phase 2 clinical trial of SL-325 in patients with Crohn's disease expected to initiate in the third quarter of 2026 – AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided recent business highlights. "

    3/5/26 6:15:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces Participation in Upcoming March Investor Conferences

    AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences: Conference Details TD Cowen 46th Annual Health Care Conference Format: Corporate presentation and one-on-one meetings Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive OfficerPresentation Date: March 2, 2026Time: 9:10 AM ETLocation: Bos

    2/25/26 8:00:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Shattuck Labs

    Cantor Fitzgerald initiated coverage of Shattuck Labs with a rating of Overweight

    4/27/26 8:21:48 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham resumed coverage on Shattuck Labs with a new price target

    Needham resumed coverage of Shattuck Labs with a rating of Buy and set a new price target of $25.00

    3/6/26 8:36:02 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Shattuck Labs with a new price target

    Piper Sandler initiated coverage of Shattuck Labs with a rating of Overweight and set a new price target of $15.00

    1/28/26 7:19:49 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    SEC Filings

    View All

    SEC Form 8-K filed by Shattuck Labs Inc.

    8-K - Shattuck Labs, Inc. (0001680367) (Filer)

    6/2/26 5:00:32 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Shattuck Labs Inc.

    144 - Shattuck Labs, Inc. (0001680367) (Subject)

    5/12/26 4:17:48 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Shattuck Labs Inc.

    10-Q - Shattuck Labs, Inc. (0001680367) (Filer)

    5/7/26 6:54:17 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Orbimed Advisors Llc bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:52:10 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ashiya Mona bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:50:52 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Redmile Group, Llc sold $166,714 worth of shares (133,371 units at $1.25), bought $166,714 worth of shares (133,371 units at $1.25), disposed of $1,283,610 worth of shares (1,026,888 units at $1.25) and acquired $1,283,610 worth of shares (1,026,888 units at $1.25) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    12/6/24 9:00:15 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Leadership Updates

    Live Leadership Updates

    View All

    Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

    AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck. "It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors," said Taylor Schre

    3/4/24 7:00:00 AM ET
    $IMNM
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

    AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023. Title: Shattuck Labs Third-Quarter 2023 Earnings Call Speakers: Taylor Schreiber, CEO; Andrew Neill, CFO; Lini Pandite, CMO Date & Time: Thursday, November 9, 2023 at 8:00 a.m. ET Dial-in Details: Toll-Free Dial-In Number: 1 (888) 440-4368 To

    11/6/23 9:28:40 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces Changes to its Board of Directors

    AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced the appointment of Dr. Carrie Brownstein, M.D., to its Board of Directors. Dr. Brownstein currently serves as the Chief Medical Officer at Cellectis. She will replace Josiah Hornblower, Shattuck's Chairman and founder, who is stepping down from the Board of Directors. George Golumbeski, Ph.D., has been appointed Chairman of the

    10/28/21 4:30:00 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Financials

    Live finance-specific insights

    View All

    Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

    – Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued –   – Prioritization to focus on SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A, intended for clinical development in inflammatory bowel disease (IBD); IND filing expected in Q3 2025 – – SL-172154 associated restructuring expected to extend cash runway into 2027 – – Company to host investor call today at 8:00 AM Eastern Time (ET) – AUSTIN, T

    10/1/24 6:30:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

    – Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontline TP53m AML patients, 33% CR/complete remission with incomplete hematologic recovery (CRi) and median overall survival had not yet been reached – – SL-172154 demonstrated a manageable interim safety profile in combination with AZA – – Focuses clinical development opportunity in HR-MDS and TP53m AML; these indications may offer the fastest path to potential approval; enrollment underway in randomized, controlled HR-MDS co

    6/14/24 6:00:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

    - Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will host an investor call for an interim safety and efficacy update from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in HR-MDS and TP53m AML, being presented at the EHA 2024 Congress. The event will feature lead investigator, Dr. Naval G. Dave

    6/6/24 7:30:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

    SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    12/6/24 9:03:38 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

    SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

    11/13/24 8:30:26 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

    SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

    11/12/24 5:01:20 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care